Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.

Autor: Herrera AL; Division of Basic Biomedical Sciences, The Sanford School of Medicine of the University of South Dakota, Vermillion, SD, United States of America., Van Hove C; Division of Basic Biomedical Sciences, The Sanford School of Medicine of the University of South Dakota, Vermillion, SD, United States of America., Hanson M; Division of Basic Biomedical Sciences, The Sanford School of Medicine of the University of South Dakota, Vermillion, SD, United States of America., Dale JB; Department of Medicine, Division of Infectious Diseases, University of Tennessee Health Science Center, Memphis, TN, United States of America., Tweten RK; Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States of America., Huber VC; Division of Basic Biomedical Sciences, The Sanford School of Medicine of the University of South Dakota, Vermillion, SD, United States of America., Diel D; Department of Veterinary and Biomedical Sciences, South Dakota State University, Brookings, SD, United States of America., Chaussee MS; Division of Basic Biomedical Sciences, The Sanford School of Medicine of the University of South Dakota, Vermillion, SD, United States of America.
Jazyk: angličtina
Zdroj: PloS one [PLoS One] 2020 Jun 23; Vol. 15 (6), pp. e0235139. Date of Electronic Publication: 2020 Jun 23 (Print Publication: 2020).
DOI: 10.1371/journal.pone.0235139
Abstrakt: Viral infections complicated by a bacterial infection are typically referred to as coinfections or superinfections. Streptococcus pyogenes, the group A streptococcus (GAS), is not the most common bacteria associated with influenza A virus (IAV) superinfections but did cause significant mortality during the 2009 influenza pandemic even though all isolates are susceptible to penicillin. One approach to improve the outcome of these infections is to use passive immunization targeting GAS. To test this idea, we assessed the efficacy of passive immunotherapy using antisera against either the streptococcal M protein or streptolysin O (SLO) in a murine model of IAV-GAS superinfection. Prophylactic treatment of mice with antiserum to either SLO or the M protein decreased morbidity compared to mice treated with non-immune sera; however, neither significantly decreased mortality. Therapeutic use of antisera to SLO decreased morbidity compared to mice treated with non-immune sera but neither antisera significantly reduced mortality. Overall, the results suggest that further development of antibodies targeting the M protein or SLO may be a useful adjunct in the treatment of invasive GAS diseases, including IAV-GAS superinfections, which may be particularly important during influenza pandemics.
Competing Interests: Dr. Dale is the inventor of certain technologies related to the development of group A streptococcal vaccines. The technology has been licensed from the University of Tennessee Research Foundation to Vaxent, LLC. Dr. Dale is the Chief Scientific Officer of Vaxent and is a member. More specifically, the vaccine used in this manuscript was the subject of a US Patent #6063386 entitled Recombinant Multivalent M Protein Vaccines, which has subsequently expired. Additional patents related to other similar vaccines have since been submitted or have issued in the US, Europe, and elsewhere. This does not alter our adherence to PLOS ONE policies on sharing data and materials without restrictions.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje